Dr. Kline is a medical oncologist who specializes in the treatment of patients with Hodgkin and non-Hodgkin lymphoma, including stem cell transplantation and CAR T cell therapy. He has expertise in the development and use of immunotherapy, and his lab research is focused on overcoming immune evasion pathways activated in blood cancers and on improving the effectiveness of immune-based treatments for people with lymphoma.
University of Chicago
Chicago
- Hematology/Oncology
2007
University of Chicago
Chicago
- Internal medicine
2004
University of Chicago
Chicago
M.D. - Medicine
2001
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy.
Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy. Cancer Immunol Res. 2026 Aug 04; 14(8):1292-1306.
PMID: 42112708
Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes.
Therapeutic targeting of BCL-2 during CART cell production augments potency through non-apoptotic adaptive changes. Signal Transduct Target Ther. 2026 Apr 27; 11(1).
PMID: 42036409
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.
Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response. Blood. 2025 May 22; 145(21):2460-2472.
PMID: 39869833
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy.
Low-Strength Type I Interferon Signaling Promotes CAR T-Cell Treatment Efficacy. bioRxiv. 2025 May 20.
PMID: 40463198
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma.
Two-stage CD8+ CAR T-cell differentiation in patients with large B-cell lymphoma. Nat Commun. 2025 May 06; 16(1):4205.
PMID: 40328775
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma.
Two-Stage CD8+ CAR T-Cell Differentiation in Patients with Large B-Cell Lymphoma. bioRxiv. 2025 Mar 15.
PMID: 40161759
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients.
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49.
PMID: 38911560
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan; 103(1):185-198.
PMID: 37851072
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL.
Optimization of Metabolic Tumor Volume as a Prognostic Marker in CAR T-Cell Therapy for Aggressive Large B-cell NHL. Clin Lymphoma Myeloma Leuk. 2024 02; 24(2):83-93.
PMID: 37827881
TIGIT is a key inhibitory checkpoint receptor in lymphoma.
TIGIT is a key inhibitory checkpoint receptor in lymphoma. J Immunother Cancer. 2023 06; 11(6).
PMID: 37364933